• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Introduction to (5-methyl-1H-indazol-3-yl)methylamine hydrochloride (CAS No. 1269225-31-1)

(5-methyl-1H-indazol-3-yl)methylamine hydrochloride, identified by its CAS number 1269225-31-1, is a significant compound in the field of pharmaceutical chemistry. This compound belongs to the indazole derivatives, a class of heterocyclic compounds that have garnered considerable attention due to their diverse biological activities. The hydrochloride salt form enhances its solubility and stability, making it a valuable intermediate in the synthesis of various pharmacologically active molecules.

The indazole core structure of (5-methyl-1H-indazol-3-yl)methylamine hydrochloride is known for its potential in drug development. Indazole derivatives have been extensively studied for their roles in modulating various biological pathways, including those related to inflammation, neurotransmission, and cancer. The presence of the methyl group at the 5-position and the amine functionality at the 3-position contributes to the unique pharmacophoric properties of this compound, enabling it to interact with specific targets in biological systems.

Recent research has highlighted the therapeutic potential of indazole derivatives in addressing chronic diseases. For instance, studies have demonstrated that certain indazole-based compounds can inhibit the activity of kinases and other enzymes involved in tumor progression. The amine group in (5-methyl-1H-indazol-3-yl)methylamine hydrochloride provides a site for further functionalization, allowing chemists to design more sophisticated molecules with enhanced binding affinity and selectivity.

In the context of drug discovery, the synthesis of (5-methyl-1H-indazol-3-yl)methylamine hydrochloride has been optimized for efficiency and scalability. Modern synthetic methodologies leverage catalytic processes and green chemistry principles to minimize waste and improve yields. These advancements ensure that pharmaceutical companies can produce this compound in sufficient quantities for preclinical and clinical studies.

The pharmacological profile of (5-methyl-1H-indazol-3-yl)methylamine hydrochloride has been investigated in various in vitro and in vivo models. Preliminary findings suggest that it may exhibit anti-inflammatory and neuroprotective effects, making it a promising candidate for treating conditions such as rheumatoid arthritis and neurodegenerative disorders. Additionally, its ability to cross the blood-brain barrier could make it useful in developing treatments for central nervous system disorders.

One of the key advantages of using (5-methyl-1H-indazol-3-yl)methylamine hydrochloride in medicinal chemistry is its versatility. It can serve as a building block for more complex molecules, allowing researchers to explore new therapeutic avenues. The compound's structural features make it compatible with a wide range of synthetic transformations, enabling the creation of derivatives with tailored properties.

The safety and efficacy of (5-methyl-1H-indazol-3-yl)methylamine hydrochloride are critical considerations in its development as a drug candidate. Extensive toxicological studies are conducted to assess its potential side effects and determine safe dosage ranges. These studies involve evaluating acute and chronic toxicity, as well as long-term effects on various organ systems. Compliance with regulatory standards ensures that any potential therapeutic benefits are balanced against safety risks.

The role of computational chemistry in understanding the behavior of (5-methyl-1H-indazol-3-yl)methylamine hydrochloride cannot be overstated. Molecular modeling techniques help predict how this compound interacts with biological targets at the atomic level. This information is crucial for designing experiments and optimizing drug candidates before they enter clinical trials. By leveraging computational tools, researchers can accelerate the drug discovery process and reduce costs associated with experimental screening.

The future prospects for (5-methyl-1H-indazol-3-yl)methylamine hydrochloride are promising, given its unique structural features and potential biological activities. Ongoing research aims to uncover new therapeutic applications and refine synthetic methods for improved production efficiency. Collaborative efforts between academic institutions and pharmaceutical companies will be essential in translating laboratory discoveries into viable treatments for human diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)